Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATAPEMBRO
2023-509457-31-00Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of pembrolizumab and ataluren in metastatic colon cancer (mCRC) and endometrial cancer (EC), sponsored by Amsterdam University Medical Center. Started May 2024; status: completed.
02
Drugs
pembrolizumabataluren
03
Conditions
metastatic colon cancer (mCRC)endometrial cancer (EC)
Beyond the preview
Go deeper on 2023-509457-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509457-31-00.